Overview

Staccato Apomorphine Single and Multi Dose PK

Status:
Completed

Trial end date:
2019-03-26

Target enrollment:

Participant gender:

Summary

This study will be conducted in 3 parts. A) compare the pharmacokinetics (PK) of a single dose of AZ-009 with that of a therapeutically-relevant dose of a commercially available apomorphine injector in healthy volunteers; B) ascending doses of active drug in healthy volunteers; and C) examine the tolerability, safety, and PK of AZ-009 in subjects with established Parkinson's disease.

Phase:

Phase 1

Details

Lead Sponsor:

Alexza Pharmaceuticals, Inc.

Treatments:

Apomorphine